Trabectedin in soft tissue sarcomas. (Q38232370)

31 August 2017

title

Trabectedin in soft tissue sarcomas. (English)

1 reference

31 August 2017

1 reference

ChEBI release 2020-05-28

Thomas Brodowicz

1

1 reference

31 August 2017

language of work or name

English

0 references

publication date

1 June 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

10

1 reference

31 August 2017

issue

8 Suppl

1 reference

31 August 2017

page(s)

s1-5

1 reference

Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.117

A review of trabectedin (ET-743): a unique mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.117

Tumor-associated macrophages as incessant builders and destroyers of the cancer stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.117

Trabectedin mechanism of action: what's new?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.117

Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.117

Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.117

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.117

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.117

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.117

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.117

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.117

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.117

Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.117

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.117

21 January 2018

Identifiers

DOI

10.2217/FON.14.117

1 reference

31 August 2017

1 reference